MNMichiko Niwa-Kawakita

Michiko Niwa-Kawakita

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michiko Niwa-Kawakita has a total of 219 co-authors. Here are the top co-authors by number of shared publications:

  • Marco Giovannini

    Department of Head and Neck Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA

    14 shared publications
  • Hugues de Thé

    Collège de France, Oncologie Cellulaire et Moléculaire, PSL University, CIRB, Institut National de la Santé et de la Recherche Médicale UMR 1050, Centre National de la Recherche Scientifique UMR 7241 1 , Equipe Labellisée par la Ligue contre le Cancer, Paris

    8 shared publications
  • Fabrice Chareyre

    Center for Neural Tumor Research, House Research Institute

    7 shared publications
  • Valérie Lallemand-Breitenbach

    Center for Interdisciplinary Research in Biology (CIRB), Collège de France, PSL research university, Inserm, Cnrs, Paris, France

    7 shared publications
  • Marie-Claude Geoffroy

    Center for Interdisciplinary Research in Biology (CIRB), Collège de France, PSL research university, Inserm, Cnrs, Paris, France

    5 shared publications
  • Laurence Goutebroze

    Sorbonne Université, CNRS UMR 8263-INSERM U1345, Institut de Biologie Paris Seine, F-75252, Paris, France

    4 shared publications

Latest Publications

  • Open Access

    Correction: PML-driven sumoylation of PML::RARA-bound repressors drives hematopoietic progenitor immortalization

    by Hsin Chieh Wu, Emmanuel Laplantine, Cécile Esnault, Michiko Niwa-Kawakita, Yi Zhang, Viviane De Almeida Bastos, Marie-Claude Geoffroy, Hugues de Thé

  • Open Access

    PML-driven sumoylation of PML::RARA-bound repressors drives hematopoietic progenitor immortalization

    by Hsin Chieh Wu, Emmanuel Laplantine, Cécile Esnault, Michiko Niwa-Kawakita, Yi Zhang, Viviane De Almeida Bastos, Marie-Claude Geoffroy, Hugues de Thé

    While acute promyelocytic leukemia (APL) is always driven by fusions involving one of the three retinoic acid receptors, why PML and RARA are the preferred fusion partners has remained largely unsettled. Here, we demonstrate that corepressor (NCoR) binding onto the RARA moiety of PML::RARA is required for hematopoietic progenitor immortalization. We establish that PML-mediated tethering of the UBC9 SUMO-conjugating enzyme onto PML::RARA enforces SUMO2 conjugation of multiple RARA partner proteins, notably the NCoR complex, boosting its repressive power. PML mutants that fail to recruit UBC9 yield PML::RARA fusions that promote neither NCoR sumoylation nor transformation. Conversely, direct UBC9/RARA fusion drives both efficient corepressor complex sumoylation and immortalization. Sumoylation inhibitors reactivate retinoic acid target genes in PML::RARA-expressing, but not in RARA-expressing, progenitors and trigger APL differentiation. Thus, fusion of PML to RARA entails an unexpected gain of function that boosts RARA-mediated transcriptional repression through sumoylation of PML::RARA-bound proteins, explaining the recurrent implication of PML and RARA in APL pathogenesis.


  • Open Access

    Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function

    by Pierre Bercier, Qian Qian Wang, Ning Zang, Jie Zhang, Chang Yang, Yasen Maimaitiyiming, Majdouline Abou-Ghali, Caroline Berthier, Chengchen Wu, Michiko Niwa-Kawakita, et al.

    PML nuclear bodies (NB) are disrupted in PML-RARA–driven acute promyelocytic leukemia (APL). Arsenic trioxide (ATO) cures 70% of patients with APL, driving PML-RARA degradation and NB reformation. In non-APL cells, arsenic binding onto PML also amplifies NB formation. Yet, the actual molecular mechanism(s) involved remain(s) elusive. Here, we establish that PML NBs display some features of liquid–liquid phase separation and that ATO induces a gel-like transition. PML B-box-2 structure reveals an alpha helix driving B2 trimerization and positioning a cysteine trio to form an ideal arsenic-binding pocket. Altering either of the latter impedes ATO-driven NB assembly, PML sumoylation, and PML-RARA degradation, mechanistically explaining clinical ATO resistance. This B2 trimer and the C213 trio create an oxidation-sensitive rheostat that controls PML NB assembly dynamics and downstream signaling in both basal state and during stress response. These findings identify the structural basis for arsenic targeting of PML that could pave the way to novel cancer drugs. Significance: Arsenic curative effects in APL rely on PML targeting. We report a PML B-box-2 structure that drives trimer assembly, positioning a cysteine trio to form an arsenic-binding pocket, which is disrupted in resistant patients. Identification of this ROS-sensitive triad controlling PML dynamics and functions could yield novel drugs. See related commentary by Salomoni, p. 2505. This article is featured in Selected Articles from This Issue, p. 2489


  • Open Access

    Author Correction: Exploration of nuclear body-enhanced sumoylation reveals that PML represses 2-cell features of embryonic stem cells

    by Sarah Tessier, Omar Ferhi, Marie-Claude Geoffroy, Román González-Prieto, Antoine Canat, Samuel Quentin, Marika Pla, Michiko Niwa-Kawakita, Pierre Bercier, Domitille Rérolle, et al.

  • Open Access

    Exploration of nuclear body-enhanced sumoylation reveals that PML represses 2-cell features of embryonic stem cells

    by Sarah Tessier, Omar Ferhi, Marie-Claude Geoffroy, Román González-Prieto, Antoine Canat, Samuel Quentin, Marika Pla, Michiko Niwa-Kawakita, Pierre Bercier, Domitille Rérolle, et al.

    Membrane-less organelles are condensates formed by phase separation whose functions often remain enigmatic. Upon oxidative stress, PML scaffolds Nuclear Bodies (NBs) to regulate senescence or metabolic adaptation. PML NBs recruit many partner proteins, but the actual biochemical mechanism underlying their pleiotropic functions remains elusive. Similarly, PML role in embryonic stem cell (ESC) and retro-element biology is unsettled. Here we demonstrate that PML is essential for oxidative stress-driven partner SUMO2/3 conjugation in mouse ESCs (mESCs) or leukemia, a process often followed by their poly-ubiquitination and degradation. Functionally, PML is required for stress responses in mESCs. Differential proteomics unravel the KAP1 complex as a PML NB-dependent SUMO2-target in arsenic-treated APL mice or mESCs. PML-driven KAP1 sumoylation enables activation of this key epigenetic repressor implicated in retro-element silencing. Accordingly, Pml−/− mESCs re-express transposable elements and display 2-Cell-Like features, the latter enforced by PML-controlled SUMO2-conjugation of DPPA2. Thus, PML orchestrates mESC state by coordinating SUMO2-conjugation of different transcriptional regulators, raising new hypotheses about PML roles in cancer.


  • Open Access

    JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML

    by Tracy Dagher, Nabih Maslah, Valérie Edmond, Bruno Cassinat, William Vainchenker, Stéphane Giraudier, Florence Pasquier, Emmanuelle Verger, Michiko Niwa-Kawakita, Valérie Lallemand-Breitenbach, et al.

    Interferon α (IFNα) is used to treat JAK2V617F-driven myeloproliferative neoplasms (MPNs) but rarely clears the disease. We investigated the IFNα mechanism of action focusing on PML, an interferon target and key senescence gene whose targeting by arsenic trioxide (ATO) drives eradication of acute promyelocytic leukemia. ATO sharply potentiated IFNα-induced growth suppression of JAK2V617F patient or mouse hematopoietic progenitors, which required PML and was associated with features of senescence. In a mouse MPN model, combining ATO with IFNα enhanced and accelerated responses, eradicating MPN in most mice by targeting disease-initiating cells. These results predict potent clinical efficacy of the IFNα+ATO combination in patients and identify PML as a major effector of therapy, even in malignancies with an intact PML gene.


  • PML nuclear bodies, membrane-less domains acting as ROS sensors?

    by Michiko Niwa-Kawakita, Hsin-Chieh Wu, Hugues de Thé, Valérie Lallemand-Breitenbach


  • Open Access

    PML is a ROS sensor activating p53 upon oxidative stress

    by Michiko Niwa-Kawakita, Omar Ferhi, Hassane Soilihi, Morgane Le Bras, Valérie Lallemand-Breitenbach, Hugues de Thé

    Promyelocytic leukemia (PML) nuclear bodies (NBs) recruit partner proteins, including p53 and its regulators, thereby controlling their abundance or function. Investigating arsenic sensitivity of acute promyelocytic leukemia, we proposed that PML oxidation promotes NB biogenesis. However, physiological links between PML and oxidative stress response in vivo remain unexplored. Here, we identify PML as a reactive oxygen species (ROS) sensor. Pml−/− cells accumulate ROS, whereas PML expression decreases ROS levels. Unexpectedly, Pml−/− embryos survive acute glutathione depletion. Moreover, Pml−/− animals are resistant to acetaminophen hepatotoxicity or fasting-induced steatosis. Molecularly, Pml−/− animals fail to properly activate oxidative stress–responsive p53 targets, whereas the NRF2 response is amplified and accelerated. Finally, in an oxidative stress–prone background, Pml−/− animals display a longevity phenotype, likely reflecting decreased basal p53 activation. Thus, similar to p53, PML exerts basal antioxidant properties but also drives oxidative stress–induced changes in cell survival/proliferation or metabolism in vivo. Through NB biogenesis, PML therefore couples ROS sensing to p53 responses, shedding a new light on the role of PML in senescence or stem cell biology.


  • Open Access

    PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination withNf2andCdkn2abloss

    by Matthieu Peyre, Céline Salaud, Estelle Clermont-Taranchon, Michiko Niwa-Kawakita, Stephane Goutagny, Christian Mawrin, Marco Giovannini, Michel Kalamarides

    PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with Nf2 and Cdkn2ab loss


  • Open Access

    Oxidative stress–induced assembly of PML nuclear bodies controls sumoylation of partner proteins

    by Umut Sahin, Omar Ferhi, Marion Jeanne, Shirine Benhenda, Caroline Berthier, Florence Jollivet, Michiko Niwa-Kawakita, Orestis Faklaris, Niclas Setterblad, Hugues de Thé, et al.

    The promyelocytic leukemia (PML) protein organizes PML nuclear bodies (NBs), which are stress-responsive domains where many partner proteins accumulate. Here, we clarify the basis for NB formation and identify stress-induced partner sumoylation as the primary NB function. NB nucleation does not rely primarily on intermolecular interactions between the PML SUMO-interacting motif (SIM) and SUMO, but instead results from oxidation-mediated PML multimerization. Oxidized PML spherical meshes recruit UBC9, which enhances PML sumoylation, allow partner recruitment through SIM interactions, and ultimately enhance partner sumoylation. Intermolecular SUMO–SIM interactions then enforce partner sequestration within the NB inner core. Accordingly, oxidative stress enhances NB formation and global sumoylation in vivo. Some NB-associated sumoylated partners also become polyubiquitinated by RNF4, precipitating their proteasomal degradation. As several partners are protein-modifying enzymes, NBs could act as sensors that facilitate and confer oxidative stress sensitivity not only to sumoylation but also to other post-translational modifications, thereby explaining alterations of stress response upon PML or NB loss.